Umideji

乌咪德吉

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameUmideji
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsN/A
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A